Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People's Republic of China.
Research context
TIANJIN PHARM DA REN TANG GRP appears in PyInvesting’s Singapore Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited is currently in a long term uptrend where the price is trading 21.0% above its 200 day moving average.
From a valuation standpoint, the stock is 91.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.7.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's total revenue sank by 9.3% to $2B since the same quarter in the previous year.
Its net income has increased by 2.4% to $185M since the same quarter in the previous year.
Finally, its free cash flow grew by 1223.0% to $206M since the same quarter in the previous year.
Based on the above factors, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited gets an overall score of 4/5.